

Reference List: CellGro® / CellGenix™ Products

## Closed Kit Systems & Cytokine Cocktail

**P.Lazarova, G. Kvalheim et al. (2008)**

Experimental attempt to produce mRNA transfected dendritic cells derived from enriched CD34<sup>+</sup> blood progenitor cells. *Cent. Eur. J. Med.* 3(1), 21-28

**S. Jarnjak-Jankovic, H. Hammerstad et al. (2007)**

A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. *BMC Cancer*, 7: 119

**J.A. Kyte, G. Kvalheim et al. (2007)**

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. *Cancer Immunol. Immunother.*, 56: 659-75

**J.A. Kyte, L. Mu et al. (2006)**

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. *Cancer Gene Therapy*, 13: 905-18

**Mu L.J., Kyte J.A., Kvalheim G. et al. (2005)**

Immunotherapy with allotumor mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. *British Journal of Cancer* 93(7): 749-56

**J.A. Kyte, G. Kvalheim et al. (2005)**

Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. *Cancer Gene Ther.*, 12(6):579-91.

**Mu LJ, Lazarova P, Gaudernack G, Saeboe-Larssen S, Kvalheim G. (2004)**

Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells. *Int J Immunopathol Pharmacol.*, 17(3): 255-63.

**Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G. (2003)**

A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. *Scand J Immunol.* 58(5):578-86.

**Querol S. (2003)**

Ex vivo production of cord blood CD34<sup>+</sup> derived myeloid precursors after serum-free static culture. *Meth Mol Biol.* 215:351-62

Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

## Reference List: CellGro® / CellGenix™ Products DC Medium and Cytokines

**A. ten Brinke et al. (2010)**

Monophosphoryl lipid A plus IFN-gamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. *Cancer Immunol Immunother.* 59(8):1185-95

**P.J. Hanley et al. (2009)**

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. *Blood* 114:1958-67

**A.M. Dohnal et al. (2009)**

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. *J Cell Mol Med* 13:125-35

**I. Möller et al. (2008)**

Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. *J Immunother.* 31(5):506-19

**L.H. Butterfield et al. (2008)**

[Clinical Study] Development of a Potency Assay for Human Dendritic Cells: IL-12 p70 Production. *J. Immunotherapy*, 31(1): 89-100

**E. Ovali et al. (2007)**

Active Immunotherapy for Cancer Patients Using Tumor Lysate Pulsed Dendritic Cell Vaccine: a Safety Study. *J. Exp. Clin. Cancer Res.*, 26(2): 209-214

**A. Curti et al. (2007)**

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. *Br. J. Haemat.*, 139(3): 415-24

**W.J. Lesterhuis, I.J.M. de Vries et al. (2006)**

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells : antigen-specific T-cell responses in DTH skin tests. *Annals Oncology*, 17:974-80

**M. Rapp et al. (2006)**

Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. *J. Neurosurg.*, 105: 41-50

**S. Jarnjak.Jankovic et al. (2005)**

Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumor mRNA as potential cancer vaccines against leukaemia. *BMC Cancer*, 5:20

**W. Lu et al. (2004)**

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. *Nature Medicine* 10(12):1359-65

**Motta M.R., Castellani S. et al. (2003)**

Generation of dendritic cells from CD14<sup>+</sup> monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. *British Journal of Hematology*, 121, 240-250

Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

## Reference List: CellGro® / CellGenix™ Products

### DC Cytokines

**T. Berger et al. (2009)**

Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS One 4:e6645

**A.-K. Thomas-Kaskel et al. (2007)**

Allogeneic HLA-Matched Donor Dendritic Cells Loaded with Patient Leukemic Blasts Preferentially Induce CD4-Positive Leukemia-Reactive Donor Lymphocytes. Acta Haematol., 117: 226-235

**M. Condomines et al. (2006)**

Functional Regulatory T Cells are Collected in Stem Cell Autografts by Mobilisation with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor. J. Immunology, 177(10): 6631-6639

**M. Erdmann et al. (2006)**

Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection. J. Immunother., 30(6): 663-674

**H. Barth et al. (2005)**

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood, 105(9): 3605-3614

**Szmania S., Yi Q., Cottler-Fox M. et al (2005)**

Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation. Cytotherapy 7(4): 374-384

**D.H. Chang et al. (2005)**

Sustained expansion of NKT cells and antigen-specific T cells after injection of  $\alpha$ -galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med., 201(9): 1503-1517

**I.M. Svane et al. (2004)**

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother, 53: 663-641

**Sorg R.V., Özcan Z., Brefort T. et al. (2003)**

Clinical-Scale Generation of Dendritic Cells in a Closed System. J Immunotherapy, 26(4):374-383

Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

## Reference List: CellGro® / CellGenix™ Products

### DC Medium

**Kalinski, P. et al. (2010)**

Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells. *Methods Mol Biol* **595**:117-33

**H.S. Garritsen et al. (2010)**

Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins. *Transfusion* **50**(4):831-42

**JJ Lee et al. (2008)**

Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. *J Leukoc Biol.* **84**(1):319-25

**H. Xiong et al. (2007)**

Enhanced interferon- $\gamma$  secretion and antitumor activity of T-lymphocytes activated by dendritic cells loaded with glycoengineered myeloma antigens. *Chin. Med. J.*, **120**(19): 1678-1684

**A. Leen et al. (2007)**

Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T Cells. *J. Immunother.*, **30**(1): 96-107

**C. Napoletano et al. (2007)**

A Comparative Analysis of Serum and Serum-free Media for Generation of Clinical Grade DCs. *J. Immunother.*, **30**(5): 567-576

**M. Wolfl et al. (2007)**

Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8<sup>+</sup> T cells responding to antigen without requiring knowledge of epitope specificities. *Blood*, **110**(1): 201-210

**I. Houtenbos et al. (2007)**

Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting. *Clin. Can. Res.* **13**(1): 307-15

**A. Gaikwad et al. (2007)**

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in *JAK2*<sup>V617F</sup> allele. *Exp. Hematology*, **35**(4): 587-94

**D.E.H. Heinemann, J.H. Peters (2005)**

Follicular dendritic-like cells derived from human monocytes. *BMC Immunology*, **6**:23

### DC Medium for T cells

**A.M. Rasmussen et al. (2010)**

Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. *J Immunol Methods.* **355**(1-2):52-60

Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

## Reference List: CellGro® / CellGenix™ Products

### SCGM and HPC Cytokines

**D.J. Steiner et al. (2009)**

Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of *ex vivo*-expanded CD34-selected umbilical cord blood cells. *Stem Cells* 27:1932-40

**H. El-Daly et al. (2005)**

Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. *Blood*, 105: 1742-49

### HPC Cytokines

**E. Zino et al. (2004)**

A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. *Blood*, 103: 1417-24

**G. Kögler et al. (2004)**

A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential. *J. Exp. Med.*, 200(2): 123-135

### SCGM for HPC

**A. Kiani et al. (2007)**

Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34<sup>+</sup> cells: regulation of Fas ligand expression of megakaryocytes. *Exp. Hemat.* 35(5): 757-770

**J. Szulc et al. (2006)**

A versatile tool for conditional gene expression and knockdown. *Nature Methods*, 3(2): 109-116

**J. Oswald et al. (2006)**

Gene Expression Profile of CD34<sup>+</sup> Hematopoietic Cells Expanded in a Collagen I Matrix. *Stem Cells*, 24(3): 494-500

### SCGM for MSC

**R. Pytlik et al. (2009)**

The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. *Biomaterials* 30(20): 3415-3427

**Manufacturer:**

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

## Reference List: CellGro® / CellGenix™ Products

# Closed Kit Systems & SCGM for NK cells

### **H. Fujisaki et al (2009)**

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. *Cancer Res* 69:4010-7

### **Milani, V., S. Stangl, R. Issels, M. Gehrman, B. Wagner, K. Hube, D. Mayr, W. Hiddemann, M. Molls, and G. Multhoff (2009)**

Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report. *J Transl Med* 7:50

## SCGM for NK cells

### **O.B. Hershkovitz (2009)**

NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. *J Immunol* 183:2610-21

### **D. Cho and D. Campana (2009)**

Expansion and activation of natural killer cells for cancer immunotherapy. *Korean J Lab Med* 29:89-96

### **E. Alici et al. (2008)**

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. *Blood*, 111(6): 3155-62

### **H. Guven et al. (2005)**

Efficient gene transfer into primary human natural killer cells by retroviral transduction. *Exp. Hemat.*, 33(11): 1320-28

### **Morris R.J., Chong L.K., Wilkinson G.W., Wang E.C. (2005)**

A high-efficiency system of natural killer cell cloning. *J Immunol. Meth.*, 307(1,2):24-33

### **Tomasec P., Wang E.C., et al. (2005)**

Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. *Nature Immunol.*, 6(2):181-88

### **Romanski A, Bug G. et al. (2005)**

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. *Experimental Hematology*, 33(3): 344-52

### **T. Igarashi et al. (2004)**

Enhanced cytotoxicity of allogenic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. *Blood*, 104(1): 170-77

### **Guven H., Gilljam M. et al. (2003)**

Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. *Leukemia*, 17: 1973-80

#### Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)

Reference List: CellGro® / CellGenix™ Products  
**AFC VueLife™ Culture Bags**

**M. de Lima et al. (2008)**

Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplantation, [E.pub.]: 1-8

**M. Hendriks et al. (2006)**

[Clinical Trial] Recovery of Regional but Not Global Contractile Function by the Direct Intramyocardial Autologous Bone Marrow Transplantation. Circulation, 114: I-101-107

**T.G. Berger et al. (2005)**

Efficient elutriation of monocytes within a closed system (Elutra™) for clinical-scale generation of dendritic cells. J. Immunol. Meth., 298(1,2): 61-72

**S.W. Krause et al. (2004)**

[Clinical Trial] Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells. Clin. Can. Res., 10: 3699-3707

Manufacturer:

CellGenix GmbH  
Am Flughafen 16 – 79108 Freiburg / Germany  
Phone: +49 761 888 89-0 – Fax: +49 761 888 89-800  
[www.cellgenix.com](http://www.cellgenix.com) – [info@cellgenix.com](mailto:info@cellgenix.com)